ZyVersa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $20.7 million pre-tax loss for Q3 2025
ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。